VEGFA and Atrophy: Although it is not possible to distinguish between the natural disease course and anti-VEGF therapy being the reason for RPE atrophy development, the linear progression over time, the association between intensity of the therapeutic regimen, and the concomitant extent of RPE loss nevertheless support this hypothesis.